AKBC member Patheon, by Thermo Fisher Scientific to help develop PharmAbcine Inc’s anti-tumour drug
21349
post-template-default,single,single-post,postid-21349,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,transparent_content,qode-theme-ver-18.2,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

AKBC member Patheon, by Thermo Fisher Scientific to help develop PharmAbcine Inc’s anti-tumour drug

AKBC member Patheon, by Thermo Fisher Scientific has entered into a strategic partnership with PharmAbcine Inc, a Korean biotech company. PharmAbcine will benefit from Thermo Fisher Scientific’s leading drug development and manufacturing capabilities including their Quick to Clinic™ integrated service offering. Thermo Fisher Scientific will help PharmAbcine progress the development of their drug, PMC-309, and its application for phase 1 clinical trials. PMC-309 is an antibody involved in inhibiting the activity of immune suppressor cells which are implicated in tumour formation.

Dr. Jin-San Yoo, CEO of PharmAbcine, remarked, “we are excited about the progress we have made with PMC-309 and strongly believe that PMC-309 will fulfill the gap in immune-oncology drug landscape.”

PharmAbcine aims to submit their phase 1 application in 2021.

Click here to read more.

Photo credit: shutterstock.com